GlobeImmune, Inc. is a biopharmaceutical company pioneering the discovery, development and manufacturing of potent, targeted molecular immunotherapies called Tarmogens for the treatment of cancer and infectious disease. The Company's lead product series, GI-4000 for the treatment of cancers of the lung and gastrointestinal tract, is currently in Phase 1 clinical trials. The Company initiated a Phase 1b trial for its second product, GI-5005, a Tarmogen for the treatment of chronic hepatitis C infection in July 2005.
This article uses content from
http://www.AboutUs.org
